Xellia Pharms Aps Drug Patent Portfolio
Xellia Pharms Aps owns 3 orange book drugs protected by 8 US patents Given below is the list of Xellia Pharms Aps's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759497 | Daptomycin formulations | 28 Aug, 2038 | Active |
| US12053502 | Daptomycin formulations | 28 Aug, 2038 | Active |
| US10039804 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US10188697 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US10849956 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11000567 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11517609 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11628200 | Glycopeptide compositions | 06 Nov, 2035 | Active |
Latest Legal Activities on Xellia Pharms Aps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Xellia Pharms Aps.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
|
Email Notification
Critical
| 20 Sep, 2023 | US11759497 |
| Recordation of Patent eGrant | 19 Sep, 2023 | US11759497 |
| Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Sep, 2023 | US11759497 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Sep, 2023 | US11759497 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
|
Email Notification
Critical
| 01 Sep, 2023 | US11759497 |
|
Issue Notification Mailed
Critical
| 30 Aug, 2023 | US11759497 |
| Dispatch to FDC | 09 Aug, 2023 | US11759497 |
|
Application Is Considered Ready for Issue
Critical
| 09 Aug, 2023 | US11759497 |
|
Issue Fee Payment Verified
Critical
| 08 Aug, 2023 | US11759497 |
|
Issue Fee Payment Received
Critical
| 08 Aug, 2023 | US11759497 |
|
Email Notification
Critical
| 24 May, 2023 | US11759497 |
Xellia Pharms Aps Drug Patents' Oppositions Filed in EPO
Xellia Pharms Aps drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15791287A | Oct, 2020 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Revoked |
Xellia Pharms Aps's Family Patents
Xellia Pharms Aps Drug List
Given below is the complete list of Xellia Pharms Aps's drugs and the patents protecting them.
1. Daptomycin
Daptomycin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759497 | Daptomycin formulations |
28 Aug, 2038
(13 years from now)
| Active |
| US12053502 | Daptomycin formulations |
28 Aug, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daptomycin's drug page
2. Vancomycin
Vancomycin is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039804 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10188697 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10849956 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11000567 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11517609 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin's drug page
3. Vancomycin Hydrochloride
Vancomycin Hydrochloride is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039804 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10188697 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10849956 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11517609 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11628200 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin Hydrochloride's drug page